ArticleScientific reports2026
Development of new liposomal formulations of quercetin - in vitro study.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Quercetin is a chemical compound present in many fruits and vegetables, known for its antioxidant and anti-inflammatory effects. Additionally, this bioactive flavonoid can induce apoptosis in abnormally developing cells. The aim of the study was to develop an effective method for encapsulating quercetin in liposomes and to evaluate the drug encapsulation efficiency, stability of the formulation and anticancer effects on melanoma cells. The results showed that quercetin can be successfully encapsulated in the aqueous phase of liposomes by complexing it with copper ions. To assess the cytotoxicity of the liposomal quercetin, SRB assays were performed on two melanoma cell lines, A-375 and C32, as well as on normal human keratinocytes, HaCaT. This formulation exhibited a cytotoxic effect on melanotic melanoma cells but not on normal cells, indicating the possible use of liposomal quercetin in anticancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.